APA (7th ed.) Citation

M, F., TF, S., SA, N., J, R., M, M., C, Z., . . . V, H. (2025). Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial. Human vaccines & immunotherapeutics, 21(1), 2579335. https://doi.org/10.1080/21645515.2025.2579335

Chicago Style (17th ed.) Citation

M, Ferguson, et al. "Immune Persistence and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus Prefusion F Protein-based Vaccine in Adults 50-59 years of Age, Including At-increased-risk Adults: A Randomized Controlled Trial." Human Vaccines & Immunotherapeutics 21, no. 1 (2025): 2579335. https://doi.org/10.1080/21645515.2025.2579335.

MLA (9th ed.) Citation

M, Ferguson, et al. "Immune Persistence and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus Prefusion F Protein-based Vaccine in Adults 50-59 years of Age, Including At-increased-risk Adults: A Randomized Controlled Trial." Human Vaccines & Immunotherapeutics, vol. 21, no. 1, 2025, p. 2579335, https://doi.org/10.1080/21645515.2025.2579335.